Table 1. Characteristics of 146 treated HIV-infected children in Johannesburg, South Africa, at the time of measurement of cell-associated HIV-1 DNA (current time) and at the time of antiretroviral therapy (ART) initiation.
| Na (%) | Median (IQR) | |
|---|---|---|
| [min, max] | ||
| Child sex | ||
| Male | 64 (43.8) | |
| Female | 82 (56.2) | |
| Age at ART start in months | 146 | 4.47 (2.96–5.76) |
| [0.79, 13.75] | ||
| Current age in years | 146 | 4.58 (3.90–5.16) |
| [3.53, 7.54] | ||
| Duration of ART until measurement in years | 146 | 4.26 (3.65–4.76) |
| [2.93, 6.40] | ||
| Current ART regimen | ||
| Efavirenz-based | 76 (52.1) | |
| Lopinavir/ritonavir-based | 70 (47.9) | |
| Current CD4 count in cells/mm3 | 140 | 1221 (977–1659) |
| [493, 3630] | ||
| Current CD4 percentage | 140 | 35.4 (30.2–40.6) |
| [17.5, 56.9] | ||
| Pre-ART CD4 count in cell/mm3 | 137 | 1396 (755–1989) |
| [21, 3677] | ||
| Pre-ART CD4 percentage | 139 | 23.4 (16.1–30.2) |
| [2.9, 80.0] | ||
| Pre-ART HIV-1 RNAb copies/ml | 127 | 750,000 (270,000–750,000) |
| [73, 73,000,000] | ||
| <100,000 | 14 (11.0) | |
| 100,000–749,999 | 36 (28.4) | |
| >750,000 | 77 (60.6) |
a Denominators are as shown and when less than 146 are explained by missing data
b Assays to quantitate HIV-1 RNA in clinical use at the time did not consistently quantitate >750,000 copies/ml